In two initiatives intended to increase the transparency of its coronavirus activities, the European Medicines Agency has published the clinical data that was used to support the EU marketing authorization of Gilead Sciences, Inc.’s Veklury (remdesivir) for COVID-19, and produced a list of all candidate medicines and vaccines on which the EMA has given advice on companies’ development plans.
The remdesivir data package consists of 64 documents and is available on the EMA’s clinical data website